The abstract is read at the publisher; the summary is JClub's.
Pegcetacoplan sustained proteinuria reduction through 52 weeks in VALIANT participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, maintaining about a 67% decrease.
- Why it matters: Proteinuria and kidney function remain difficult to control in these glomerular diseases, and longer-term durability beyond the prespecified 26-week endpoint is clinically important.
- What they did: In the 26-week randomized, placebo-controlled period (pegcetacoplan n=63 vs placebo n=61) followed by an open-label extension, exploratory outcomes were assessed at week 52, including urine protein-to-creatinine ratio and eGFR.
- The result: At week 52, pegcetacoplan-to-pegcetacoplan showed urine protein-to-creatinine ratio change -67.2% [-75.8 to -55.4] and eGFR change -3.7 mL/min/1.73 m2 [-8.9 to 1.6], with no new safety concerns.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.